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A suitable emulgel formulation of piroxicam was prepared and its percutaneous permeation was investigated 
using Wistar rat skin and diffusion cell technique. The concentrations of the drug in receptor phase of 
diffusion cells were measured using HPLC method. The effect of three types of penetration enhancers (Myrj 
52, cineol and Transcutol P) with different concentrations on transdermal permeation of the drug was also 
evaluated. Flux, Kp and enhancement ratios (ERs) of piroxicam in the presence of enhancers was measured 
and compared with emulgel base alone and simple commercial gel. The results showed a significant 
enhancement in the flux from emulgel base compared to hydroalcoholic gel formulation (9.91 folds over 
simple gel). The highest enhancement ratio (ER=3.11) was observed for Myrj 52  at the concentration of 
0.25%. Higher concentrations of Myrj 52did not show any enhancement in the drug flux due to micelle 
formation and solubilization of the drug by micelles. The increase in solubility, in turn, increases the 
saturated concentration and reduces the thermodynamic activity of the drug. Transcutol® P with 
concentrations higher than 0.25% w/w showed burst transportation of the drug through the skin. All 
concentrations of cineol and Transcutol did not show any enhancing effects over emulgel base alone (ER <1). 
 





Non-steroidal anti-inflammatory drugs 
(NSAIDs) play an important role in reducing 
inflammation and pain. However, NSAIDs are 
associated with gastrointestinal side effects 
and generally cause gastritis due to inhibition 
of cyclooxygenase-2 and in some cases 
cyclooxygenase-1 (1). These side effects can 
be overcome by topical administration of these 
drugs (2). The transdermal administration of 
these drugs has several advantages over other 
routes of administrations (3). 
Human skin is a remarkably efficient barrier 
compared to other biological membranes. 
Hence, low permeability of the skin makes 
difficulties for the percutaneous delivery of 
therapeutic agents. In the last decade, several 
studies about NSAID formulations in lipid 
base (4) and Pluronic lecithin organogel (5, 6) 
have been reported. Gel formulations of 
piroxicam do not exhibit satisfying 
percutaneous absorption and hence, 
formulation of piroxicam in emulgel dosage 
forms would be more desirable. Emulgels are 
oil-in-water emulsions in which the external 
phase is in the gel form. Several studies have 
shown that the amount of drug absorbed from 
emulgel formulations was higher than that 
absorbed from simple hydroalcoholic gel 
formulations (7). Efforts have, therefore, been 
focused on developing methods and 
formulations to increase the permeability of 
human stratum corneum to these drugs. One 
promising approach to overcome barrier 
property of the skin is using skin penetration 
enhancers, which can increase the permeability 
of the stratum corneum (8) to drugs. Different 
groups of chemicals have been reported as 
transdermal penetration enhancers (9) which 
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include surfactants, organic solvents, 
unsaturated fatty acids and also organic 
materials which are extracted from natural 
sources such as alkaloids and terpenes. Some 
of the studies have been carried out to predict 
the percutaneous absorption of piroxicam 
using different permeation enhancers (10-13).  
In the present study, the penetration 
enhancing effect of emulgel formulations of 
piroxicam was compared to that of a simple 
gel formulation of this drug. The effects of 
some skin penetration enhancers on the skin 
permeation of piroxicam were also investigated. 
Penetration enhancers with different chemical 
structures, namely non ionic surfactants (Myrj 
52), terpenes (cineol) and synthetic chemical 
penetration enhancers (Transcutol P) with 
different concentrations were studied. Myrj 52 
(polyoxyethylene 40 stearate) is a nonionic 
surfactant with very low toxicity and irritancy 
which is widely used in pharmaceuticals and 
cosmetic formulations as emulsifier and 
stabilizer. Transcutol P is a wide range  
solvent which also has penetration enhancing 
ability for some drugs. Cineol is a terpene        
and has found applications as an adjuvant in 
the form of penetration enhancers for 
improving transdermal and transmucosal drug 
delivery. 
 
MATERIALS AND METHODS 
 
Materials 
Piroxicam was generously provided by 
Zahravi Industrial Co. (Tabriz, Iran). Pluronic® 
F127 was purchased from Sigma-Aldrich Co. 
(USA), Carbopol® 940 from B.F. Goodrich 
Co. (USA), hydroxypropyl methylcellulose 
K4M from Colorcon Co. (UK), Transcutol P 
from GattefÖsse (France), and Myrj 52 from 
Croda Chemical Co. (Switzerland). Isopropyl 
Myristate, Methyl paraben, soya lecithin, 
propylene glycol, monobasic potassium 
phosphate, sodium hydroxide, methyl paraben, 
liquid silicone, silicon grease, cineol, 
triethanolamine, glacial acetic acid, 
triethanolamine, acetonitrile and sodium 
acetate were supplied by Merck (Darmstadt, 
Germany). Commercially available piroxicam 
gel was obtained from Razak Pharmaceutical 
Co. (Karaj, Iran) . 
Methods 
Preparation of piroxicam emulgels 
Emulgels are oil-in-water emulsions which 
are converted to gel by mixing with a gel 
forming agent (14). To develop a stable 
emulgel formulation, selection of proper gel 
forming agent, emulsifier and organic phase 
are of importance. For preparation of 
piroxicam emulgel, three types of gelling 
agents including Pluronic F127, 
hydroxypropylmethyl cellulose (HPMC) and 
Carbopol 934 were used. To achieve an 
emulgel with desirable characteristics, several 
formulations were prepared using different 
types and amounts of gel forming agents, 
emulsifiers, organic phase composition, and 
drug solvent. 
Formulations were prepared at laboratory 
scale at room temperature by dissolving 
piroxicam in propylene glycol as a moisturizer 
and solubilizer. A fixed concentration of the 
drug was used in all cases to allow the 
comparison of the effect of vehicles on the 
percutaneous absorption of piroxicam. The pH 
of all prepared emulgels was adjusted to 6-6.5 
using citric acid or triethanolamine. The 
enhancers were added to the organic phase 
(containing lecithin and isopropyl myristate in 
the ratio of 4:1) before the addition of the gel 
phase into the organic phase. The 
compositions of the prepared formulations are 
shown in Table 1. 
Formulations containing HPMC 1% w/w 
(F1-F5) did not exhibit appropriate 
consistency. Therefore, to obtain desirable gel 
with suitable thickness, 2% w/w HPMC was 
used which resulted in formulations F6-F10. 
Though the amount of HPMC was increased, 
these formulations did not show desirable 
physical stability. HPMC with a concentration 
of 3% w/w produced (F11-F15) very thick gels 
whose incorporation with other ingredients of 
the formulation was difficult.  
Emulgels containing Carbopol 940 as a gel 
forming agent did not result in a uniform and 
homogeneous gel (F21-F25). Therefore, these 
formulations were not considered for further 
experiments. Formulations prepared using 
Pluronic F127 (F16-F20) showed desirable 
characteristics and appearance. These 
formulations were kept at 40°C for a period of 
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Table 1. Composition (% w/w) of the formulations containing HPMCK4M, Pluronic® F127, and Carbopol® 940. All 
formulations contained 0.5% (w/w) piroxicam and 10% (w/w) propylene glycol 









F1  18 71.5 - - - - 
F2 20  69.5 - - - - 
F3  22 67.5 - - - - 
F4 22 62.5 - - - - 
F5 30 59.5 - - - - 
F6 18 - 71.5 - - - 
F7 20 - 69.5 - - - 
F8 22 - 67.5 - - - 
F9 22 - 62.5 - - - 
F10 30  59.5 - - - 
F11 18 - - 71.5 - - 
F12 20 - - 69.5 - - 
F13 22 - - 67.5 - - 
F14 22 - - 62.5 - - 
F15 30 - -  59.5 - - 
F16 18 - - - 71.5 - 
F17 20 - - - 69.5 - 
F18 22 - - - 67.5 - 
F19 22 - - - 62.5 - 
F20 30 - - - 59.5 - 
F21 18 - - - - 71.5 
F22 20 - - - - 69.5 
F23 22 - - - - 67.5 
F24 22 - - - - 62.5 
F25 30 - - - - 59.5 
 
 
Table 2. Composition (% w/w) of selected formulations containing penetration enhancers (all formulations contained 
0.5% piroxicam, 18 ml organic phase and 10 ml propylene glycol). 
Formulation name Pluronic F127  Myrj 52 Transcutol P Cineol 
F26       71.25 0.25 - - 
F27   71 0.5 - - 
F28       70.25 1 - - 
F29        69.25 2 - - 
F30       71.25 - 0.25 - 
F31  71 - 0.5 - 
F32      70.25 - 1 - 
F33      69.25 - 2 - 
F34     71.25 - - 0.25 
F35 71 - - 0.5 
F36      70.25 - - 1 
F37     69.25 - - 2 
 
two months in order to assess their physical 
stability based on their appearance in terms of 
microbial contamination and phase separation. 
For the sake of comparison, formulation F16 
(with no penetration enhancer) was selected as 
the “base emulgel formulation” due to its 
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better stability and physicochemical properties 
over other formulations containing no enhancer. 
This formulation was used as the base for 
evaluation of the efficiency of some penetration 
enhancers on percutaneous absorption of 
piroxicam through the rat skin. To this end, 
three types of skin penetration enhancers 
including Transcutol P, Myrj 52 and cineol 
were examined at different concentrations 
(0.25, 0.5, 1 and 2% w/w). Percutaneous 
absorption of the drug through the rat skin in 
the presence of these penetration enhancers 
were assessed using a Franz diffusion cell. 
Details of prepared formulations are reported 
in Table 2.  
 
In vitro permeation studies 
The abdominal hair of Wistar male rats, 
weighing 180-200 g, was shaved using an 
electric razor after scarifying animals using 
excess ether anesthesia 24 h before the 
treatment. The experiments were performed in 
accordance with ethical committee of the 
Tabriz University of Medical Sciences. The 
abdominal skin was surgically removed and 
adhering subcutaneous fat was carefully 
cleaned. To remove extraneous debris and 
leachable enzymes, the dermal side of the skin 
was kept in contact with a normal saline 
solution up to one h before starting the 
diffusion experiment. The skins were mounted 
on the Franz-type diffusion cells (Erweka 
HDT6, Germany) with an available diffusion 
area of 5.1 cm2 with the stratum corneum 
facing the donor compartment. All six Franz 
cells were placed on the skin penetration study 
apparatus. Each set of experiments was 
performed with minimum 3 diffusion cells 
(n ≥3) and repeated 3 times in different days. 
28.5 ml of phosphate buffer solution (pH=7.4) 
was used as the receptor medium and 0.5 g of 
the emulgel was placed on the skin surface in 
the donor compartment. The temperature of 
the receptor medium was maintained at 37°C 
by circulating of warm water between two 
layers of the diffusion cells and contents of 
receptor medium were stirred magnetically at 
600 rpm. Samples of 1 ml were withdrawn 
from the receptor compartment at 15, 30, 60, 
120 and 240 min and replaced with the same 
volume of phosphate buffer solution at 37°C to 
maintain the volume constant. The amount of 
piroxicam in the receptor phase was assayed 
with HPLC apparatus.  
 
Analytical procedure 
The HPLC apparatus (Shimadzu VP-Japan) 
equipped with UV detector (Shimadzu SPD-
10A VP) and an ODS C18 (250×5 mm, 5 µm) 
(Shimadzu, Japan) HPLC column were used to 
perform the analysis. The mobile phase 
consisted of sodium acetate- acetonitrile 
(61:39) mixture which was adjusted at pH 4.0 
by glacial acetic acid and eluted at the flow 
rate of 1.5 ml/min and the effluent was 
monitored at 330 nm using a UV detector (15). 
20 µl of sample was injected into the HPLC 
column. The retention time of piroxicam at 
this HPLC condition was 11 min. Calibration 
curve with standard concentrations ranging 
from 0.125 to 2 µg/ml of piroxicam in 
phosphate buffer was constructed to measure 
the drug concentration in the samples. 
 
Data treatment 
According to Fick’s second law of 
diffusion, the total amount of drug (Qt) 
appearing in the receptor solution in time t is 
expressed as: 
 
where, A is the effective diffusion area, C0, 
represents the drug concentration which 
remains constant in the vehicle, D is the 
diffusion coefficient; L denotes the thickness 
of the membrane and K is the partition 
coefficient of the drug between membrane and 
vehicle. At steady-state is expressed as 
follows: 
 
The flux, J, was determined from the slope 
of the steady-state portion of the amount of the 
drug permeated divided by A versus time. The 
lag time values were determined from the x-
intercept of the slope at steady-state. The flux 
is expressed as: 
 
where, Kp is the permeability coefficient.  
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The ER was calculated from the following 
equation (16). The values reported are mean 





Fig. 1(a) shows the permeation profiles of 
the drug from commercially available 
piroxicam hydroalcoholic simple gel and 
emulgel base formulation (F16). As shown in 
this figure, the permeation rate of the drug 
from emulgel base is significantly higher than 
that of hydroalcoholic gel. The flux of 
piroxicam from emulgel base (F16) was found 
to be 1.428 µgcm-2h-1 which is 9.92 folds 
higher than that of the commercial simple gel 
formulation (0.144 µgcm-2h-1). These results 
showed that the type of base could greatly 
influence the transdermal flux of the drug. 
Emulgel bases are also more compatible with 
the skin compared with alcoholic or 
hydroalcoholic gels (17). 
Fig. 1(b) shows the transdermal permeation 
of the drug from different emulgel 
formulations containing various concentrations 
(0.25, 0.5, 1 and 2% w/w) of Myrj 52. As 
shown in this figure, the highest ERs (Table 3) 
were observed in the presence of Myrj 52 at 
0.25% w/w concentrations (ERs=3.11) . 0.25% 
0.25% w/w concentrations (ERs=3.11). 
Enhancement of the drug transport rate may 
relate to the ability of the surfactant molecules 
to penetrate the skin and increase its 
permeability. The ER values reduced when the 
higher amount of Myrj 52 was used (ER was 
0.289 and 0.046 for 1% and 2% w/w 
respectively). 
Piroxicam permeation profiles from 
formulations contained different percent of 
Transcutol P are shown in Fig. 2(a) and their 
corresponding parameters including fluxes and 
ERs are reported in Table 3. As seen in        
Fig. 2(a), all the concentrations of Transcutol 
P except 0.25% w/w could permeate their drug 
content into the skin as the burst transportation 
(18, 19). In these cases, two stages are seen in 
the profile of the amounts of the drug 
permeated per unit area of the skin versus time 
where the first stage is due to the burst 
transportation and the second stage is related 
to the steady state condition of the drug 
permeation. A direct relationship was observed 
between the amounts of piroxicam penetrated 
into the skin and the concentrations of the 
enhancers at the initial sampling times. Burst 
transportation of the drug in the presence of 
Transcutol P at 1% and especially 2% (F32 
and F33) concentration was initiated 
immediately whereas in the case of the 
formulation containing 0.5% Transcutol P (F31), 
Table 3. Flux values, Permeablity coefficients (Kp) and enhancement ratios of evaluated formulations 
Enhancer concentration (%w/w) Steady- state flux (µgcm-2h-)1) Kp (×103; cm h−1) E.R. 
Commercial gel (Razak) 0.144±0.053 0.0288±0.011 0.101 
Emulgel base without enhancer  1.428±0.703  0.2856±0.141 1.000 
                                                                                         Myrj 52  
0.25 4.440±1.807 0.8880±0.036 3.110 
0.50 3.978±1.504 0.7956±0.301 2.785 
1.00 0.414±0.008 0.0828±0.002 0.289 
2.00 0.066±0.014 0.0132±0.003 0.046 
                                                                                        Transcutol P  
0.25 1.194±0.891 0.2388±0.178 0.836 
0.50 0.228±0.071 0.0456±0.014 0.117 
1.00 0.366±0.118 0.0732±0.024 0.256 
2.00 0.387±0.038 0.0774±0.008 0.277 
                                                                                        Cineol  
0.25 0.186±0.069 0.0372±0.014 0.130 
0.50 0.702±0.302 0.1404±0.060 0.491 
1.00 0.144±0.078 0.0288±0.016 0.101 
2.00 0.588±0.198 0.1176±0.040 0.412 
 




the burst transportation started 30 min after 
contacting with the skin. The burst transportation 
was not observed when the concentration of 
Transcutol P in the formulation was reduced 
from 0.5% to 0.25% w/w (F30). 
Drug permeation profiles of emulgel base 
formulations containing different concentrations 
of cineol as penetration enhancer are shown in  
Fig. 2(b). Cineol did not show a significant 
improvement in the flux of piroxicam through 
the rat skin (P>0.05). The results showed that 
none of the used concentrations of cineol 
could improve the flux of piroxicam compared 
to emulgel base alone (Table 3).  
Based on the data reported in Table 3, ERs 





Fig. 1. Piroxicam skin permeation from (a), emulgel base alone (F16) and commercial gel formulations and (b), the 







Fig. 2. Transdermal permeation profiles of piroxicam from emulgel formulations containing different concentration of 






Fig. 3. Permeation profiles of the drug from (a), commercial gel, emulgel base alone and emulgel base plus Myrj 52 
with 0.25% w/w concentration (F26) (b), Enhancement ratios of different concentrations of various penetration 
enhancers. 
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base were below 1 which indicates that all 
concentrations of cineol have decreased 
permeation rate of piroxicam compared to 
emulgel base alone. 
Fig. 3(a) shows the skin permeation profiles 
of the drug from commercial gel, emulgel base  
formulation and emulgel base in the presence 
of 0.25% Myrj 52 as the penetration enhancer 
(F26) which indicated the highest enhancement 
ratio between various concen-trations of the 
three types of the used penetration enhancers 
(ER=3.11). As shown in this figure, F26 
showed significantly greater permeation rate in 
comparison with emulgel base alone. 
The plot of ERs versus various 
concentrations of the penetration enhancers is 
shown in Fig. 3(b). As it is clear from this 
figure among three penetration enhancers used 
in the present study, only Myrj 52 with 
concentrations below 0.5% w/w showed ERs 
greater than emulgel base alone. On the other 
hand, all concentrations of Transcutol P and 
cineol showed lower flux than emulgel base 
alone (ERs <1). This diagram also clearly 
shows that in order to achieve the highest ER 
value, an optimum level of the enhancer is 
needed. This figure also demonstrates that the 
nature and physicochemical properties of the 
drug molecule and the enhancers are very 
important factors in enhancing the skin 




Piroxicam exhibits a weakly acidic 4-
hydroxy proton (pKa, 5.1) and weakly basic 
pyridyl nitrogen (pKa, 1.8); thus, the pH of 
medium can play an important role in its 
solubility in aqueous solutions. Topical 
preparations of this drug are usually 
formulated in the pH range of 6-6.5 to increase 
the skin compatibility and to reduce skin 
irritancy. In a simple aqueous or 
hydroalcoholic gel with pH of 6, about 87% of 
piroxicam is in the ionized form. Intrinsic logP 
octanol/water of piroxicam is 3.06 (20) which 
indicates that the solubility of non-ionized 
form of the drug in octanol is much greater 
than that of the aqueous solutions (more than 
1000 times). In the emulgel formulations, the 
non-ionized portion of the drug mainly enters 
the organic phase which is isolated from the 
aqueous phase of the emulgel. In this situation, 
a given amount of ionized drug in aqueous 
phase converts to non-ionized form to 
maintain the equilibrium between two forms of 
the drug in aqueous phase of the emulgel 
formulation. This process is continued until 
the majority of the drug dissolves in the oily 
phase in the form of non-ionized which has 
ability to penetrate into the skin. This causes a 
significant increase in the drug concentration 
and the thermodynamic activity of non-ionized 
form of the drug which is considered as 
effective form of the drug in transdermal 
absorption. Hence, the great enhancement in 
penetration of the drug into the skin was 
observed. Another advantage of emulgels over 
hydroalcoholic gels is related to physiological 
and structural characteristics of the skin. 
Emulgels are alcohol free formulations. 
Alcohol can cause the irritation of the skin 
especially dry skins due to its ability to 
dissolve and remove natural lipids of stratum 
corneum.  
Myrj 52 or polyoxyethylene 40 stearate are 
nonionic surfactants. Several studies have 
reported the enhancing effects of nonionic 
surfactants on transdermal and transmucosal 
permeation of the drugs (19-22). There are two 
possible mechanisms involved in the 
enhancement of drug transport by nonionic 
surfactants (23, 24). Initially, the surfactants 
may penetrate into the intercellular regions of 
the stratum corneum, increase the fluidity of 
lipids and eventually solubilize and extract the 
lipid components. Secondly, penetration of the 
surfactant into the intracellular matrix 
followed by interaction with and binding to 
keratin filaments may result in a disruption 
within the corneocytes. Myrj 52 is thought to 
enhance the permeation of the drug by 
disruption of lipid arrangement in the stratum 
corneum and to increase water content of the 
proteins in the barrier. Oxyethylene units and 
long hydrocarbon chain in the structure of 
Myrj 52, allow partitioning between lipophilic 
mortar substance and the hydrophilic protein 
domains. It can also interact with polar head 
groups of the skin lipids and the modification 
of H-bonding and ionic forces may occur. The 
other possible mechanism is related to keratin 
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fibrils and their associated water molecules as 
targets of enhancers. The disruption caused by 
the enhancer makes this area more aqueous. 
With high enough volumes, an increase in 
solubilizing ability of the aqueous layer could 
result in the operational partition coefficient of 
this region of the skin (25). This would then 
allow the drug transport through the corneocytes.   
As it is clear from Fig. 1(b), the ER values 
reduced when higher amount of Myrj 52 was 
used (ER was 0.289 and 0.046 for 1% and 2% 
w/w respectively). This could be explained by 
the fact that surfactants are able to produce 
micelles in concentrations higher than their 
critical micelle concentration (CMC) in the 
related medium or base. Although the CMC 
concentration of non ionic surfactants in pure 
water is relatively low (lower than 0.1% w/w), 
it has been shown that the presence of other 
water miscible cosolvents such as propylene 
glycol increases their CMC up to ten-fold 
compared to pure water (26). Surfactant 
micelles can interact with drug molecules and 
increase their solubility. Solubilization of the 
drug by surfactant micelles decreases the 
thermodynamic activity of the drug and, 
hence, decreases the driving force of the drug 
absorption. These results are in agreement 
with our previous works (19, 20). 
Transcutol P is soluble both in water and oil 
and can form an intracutaneous depot for 
drugs used in topical formulations. Piroxicam 
permeation profiles in Fig. 2(a) indicate that 
the enhancer can penetrate into the skin 
rapidly and depot in the skin due to its 
physicochemical properties and high solvency 
effects to aqueous and oily medium. The drug 
can co-transport with the enhancer which led 
to a high drug permeation rate in a short period 
of time. Afterward, the transportation of 
piroxicam reaches to an equilibrium or steady 
state and permeation of the drug across the 
skin is performed by a constant rate. At low 
concentrations (0.25% w/w), Transcutol P 
cannot transport the drug across the skin 
immediately after contacting with the skin and 
hence, burst transportation was not seen. As 
shown in Table 3, all tested concentrations of 
Transcutol P showed lower ERs in comparison 
with emulgel base alone. The saturated 
concentration of the non-ionized drug in 
organic phase of the emulgel increases in the 
presence of Transcutol P whereas the total 
amount of the drug in the formulation is 
constant. This resulted in the reduction of the 
relative solubility of the non-ionized form of 
the drug  and consequently a reduction in the 
thermodynamic activity of the drug in the skin 
permeation process.  
Cineol or eucalyptol is a terpene ether 
which is naturally obtained from eucalyptus 
extract.  Terpenes like menthol, cineole, and 
limonene have been used to enhance 
permeation of both hydrophilic and lipophilic 
drugs (27). Cineole is reported to be the most 
efficient penetration enhancer for propranolol 
hydrochloride across the rat skin, compared 
with menthol and propylene glycol (28). In a 
separate study, Nokhodchi and coworkers 
investigated the effect of different terpens on 
the penetration of diclofenac sodium from the 
rat skin and they concluded that the most 
outstanding penetration enhancer was 
nerolidol, providing an almost 198-fold 
increase in the permeability coefficient of 
diclofenac sodium, followed by farnesol with a 
78-fold increase in skin permeability (29). 
Cineol like other terpenes exerts its enhancing 
effect by interacting with intercellular stratum 
corneum lipids to increase the diffusivity, but 
its acceleratory effects are not the result of 
partitioning (9). Neither partition coefficient 
nor thermodynamic activity was altered by the 
terpenes. It is suggested that the possible 
mechanism of permeation enhancement of the 
drugs by terpenes is the result of the 
modification of skin barrier properties It has 
been shown that terpenes with minimal degree 
of unsaturation like menthol and cineol are 
good sorption promoters for polar and water 
soluble drugs (28,30).  
Despite several reports regarding the 
enhancing effect of cineol on transdermal flux 
of some drugs such as propranolol and 
zidovudine (31), cineol did not show a 
significant improvement in the flux of 
piroxicam through the rat skin in the current 
study (P>0.05). This could be due to the high 
lipophilicity of piroxicam (water solubility of 
piroxicam is 23 mg/L (32). It has been 
reported that the optimum permeation 
enhancing effect of cineol observed in the case 
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of polar and water soluble drugs (27,30). Apart 
from this, it seems that cineol can interfere 
with skin permeation of piroxicam with other 
mechanisms.  Experimental Log P oct/water of 
cineol is reported to be 2.74 (33), which is 
close to the log P of piroxicam (3.05). This 
indicates that cineol may compete with the 
non-ionized form of the drug in entering the 
oily phase of the emulgel and switch the 
ionization equilibrium of the drug toward the 
production of ionized form in the aqueous 
phase due to the low volume of oily phase of 
the formulation (about 3.5% w/w) and its 
limited capacity of dissolving lipophilic 
substances. The authors called this 




Piroxicam is more efficiently transported 
across the skin from emulgels compared to 
hydroalcoholic gels. Penetration enhancers can 
markedly increase the transdermal absorption 
of piroxicam if the type and concentration of 
the enhancer in formulation is optimized. The 
results revealed that Myrj 52 resulted in the 
greatest enhancing activity at concentrations 
lower than 0.5% w/w for emulgel formulations 
containing piroxicam. The results of this study 
show that the type and concentration of 
penetration enhancers and base of the 
formulation are very important variables and 
should be optimized for achieving an efficient 
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